Triptolide Transcriptionally Represses HER2 in Ovarian Cancer Cells by Targeting NF-κB
Figure 4
NF-κB prevents the reduction of HER2 expression caused by treatment with TPL. NIH3T3 cells were transfected with NF-κB-p65 or -p50 (2 μg) or vector only. After 6 h, TPL (100 nM) or vehicle was added to the medium for 24 h. Luciferase assays were performed to detect HER2-F1 (a) and HER2-F4 (b) promoter activities. (c) SKOV-3 (d), TOV-21G (e), and OVCAR-3 cells were transfected with NF-κB-p65 or -p50 (2 μg) or vector only for 24 h and then treated with TPL or vehicle for another 24 h. Cell lysates were immunoblotted with antibodies specific for HER2/neu, p-HER2, NF-κB-p65, NF-κB-p50, or actin.
